To examine the impact that mutant p53 has on disease progression and response to targeted therapies in CLL, we generated Eμ-TCL1 mice carrying one copy of the R172H hot-spot mutation (corresponding to the R175H mutation observed in human cancers). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.